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patients with AD have been found to have increased IgE levels 
and high-affi nity receptors for IgE [1] it can be assumed that 
treatment with an anti-IgE antibody may decrease clinical 
manifestations and disease activity. 
To test this hypothesis, we conducted a study in patients 
with a diagnosis of severe AD (SCORAD score >50 points) 
from the allergy service at Hospital Adolfo López Mateos in 
Mexico City, Mexico over a period of 10 months. A complete 
clinical history was taken and laboratory tests, including IgE, 
were requested. Omalizumab treatment was started with doses 
adjusted to weight and IgE levels. Patients were periodically 
evaluated, with physical examination and assessment of 
SCORAD score, use of drugs, presence of adverse effects, 
and quality of life using the Dermatology Life Quality Index 
(DLQI) [6].
The software program SPSS 15.0 for Windows was used 
for statistical analyses.
Eleven patients (1 male and 10 females) aged between 12 
and 52 years with severe AD were enrolled. 
The baseline SCORAD score ranged from 43 to 101 points, 
with a mean of 71.2 points. A gradual improvement was seen 
in all patients, with a mean of 31.54 points after 10 months 
(P<.05). Mean (SD) quality-of-life scores also improved, from 
9.36 points to 3.72 (1.48) over the same period (P<.05) 
There have been previous reports of AD treated with 
omalizumab. Vigo [7] reported a signifi cant improvement in 
the symptoms of all 7 patients treated, and Belloni et al [8] 
reported a favorable response in 6 of 11 patients. Krathen and 
Hsu [9], however, observed no response to omalizumab in 3 
patients with severe AD.
In our patients, there was a gradual improvement in 
SCORAD scores, accompanied by a decrease in symptoms 
and an improvement in quality of life, with fewer limitations 
in terms of attendance at school, work, etc. No adverse effects 
were observed.
The limitations of this study are the small sample size and 
the lack of comparison with a placebo group. 
Omalizumab treatment progressively decreased the 
severity of AD, evaluated by SCORAD, with a gradual 
decrease in symptom intensity, which was reflected by 
improved quality-of-life scores. 
It is necessary to conduct studies with more patients 
and, if similar results to the ones presented here are found, 
omalizumab may become a fi rst-line therapy, capable of 
achieving good disease control and preventing complications 
in the treatment of moderate and severe AD.
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Although there have been few reports of lipoatrophy as a 
cutaneous side effect of recombinant human insulin or insulin 
analogues, in recent years, there have been an increasing 
number of case reports and letters in the scientifi c literature 
indicating that lipoatrophy may also develop after treatment 
with these insulins [1-5]. Immunological mechanisms have 
been proposed, but the exact pathogenesis of lipoatrophy 
remains obscure [6].
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Table. Specifi c Immunoglobulin (Ig) G and IgG4 Subclass Values and Precipitin Study Results
  
                          Patient                        Control  Patient Control 1 Control 2
  IgG, mg/mL IgG4, mg/mL IgG, mg/mL IgG4, mg/mL  Precipitins 
  
 Apidra  2.84 0.06 0 0 (-) ND ND
 Humalog  2.73 0.04 0 0 (-) ND ND
 Novorapid 2.59 0.05 0 0 (-) ND ND
 Actrapid  2.62 0.01 0 0 (+) (-) (-)
 Insulatard 6.94 0.02 0 0 (+) (-) (-)
 Levemir  3.38 0.08 0 0 (+) (-) (-)
 Lantus  45.3 0.02 27.4 0 (+) (-) (-)
 Protamine 3.44 0.05 0 0 (+) (-) (-)
Abbreviations: ND, not done.
A 30-year-old woman, diagnosed 2 years previously 
with type 1 diabetes mellitus and primary autoimmune 
hypothyroidism, had experienced a severe depression of the 
skin surface consistent with lipoatrophy over the past year; 
the depression affected the sites where she administered 
subcutaneous insulin. During this time, she had used different 
types of insulins, including short-acting insulin (insulin 
glulisine [Apidra]), insulin lispro [Humalog], insulin aspart 
[Novorapid]; long-acting insulin (insulin detemir [Levemir] 
and insulin glargine [Lantus]); and premixed insulin (insulin-
aspart + isophane insulin [Novomix]). She did not relate the 
lipoatrophic areas with the administration of a specifi c insulin.
Sk in  b iopsy  o f  t he  l i poa t roph i c  a r ea s  and 
immunofl uorescence against immunoglobulins, complement 
fractions, and fibrinogen were performed. Skin prick, 
intradermal, and patch tests were performed with all the 
insulins she had been using as well as with human insulin 
(Actrapid), isophane insulin (Insulatard), and protamine. The 
results were read at 20 minutes and at 48 and 96 hours. Specifi c 
immunoglobulin (Ig) G and IgG4 subclass were measured by 
biotinization using ImmunoCAP (Phadia, Uppsala, Sweden) 
and precipitins against human insulin, protamine, and all the 
insulins mentioned above were determined by the Ouchterlony 
technique. Specifi c IgE against human insulin and protamine 
were also measured.
In vivo skin tests (prick, intradermal, and patch tests) and 
specifi c IgE against human insulin and protamine were negative 
(<0.35kU/L). High levels of IgG and IgG4 were observed for 
all the insulins tested as well as for protamine, with higher 
levels noted for medium- (Insulatard) and long-acting insulins 
(Levemir and Lantus) than for short-acting insulins (Table). 
As a control for the IgG and IgG4 determinations, a mixed 
pool of neonatal sera was used, with negative results for all 
the insulins tested, except for Lantus, which yielded high 
IgG levels. The precipitin study was positive for Actrapid, 
Insulatard, Levemir, Lantus, and protamine and negative 
for Apidra, Humalog, and Novorapid (Table). Two patients 
with diabetes who had used these insulins in the past served 
as controls and showed negative precipitins against all the 
insulins tested. The skin biopsy showed lipoatrophy, with some 
areas of infl ammatory neutrophilic infi ltrate but no signs of 
immunoglobulins, complement factors, or fi brinogen deposits 
in the immunofl uorescence study.
The positive IgG result for 1 insulin in the control sera 
rendered this measurement useless, and it was therefore 
decided to select an alternative insulin based on the results 
of the precipitin study. All the long-acting insulins tested 
had yielded positive results in this study and therefore, after 
consultation with the patient, it was decided to start continuous 
subcutaneous insulin infusion with insulin glulisine (Apidra), 
for which the precipitin study had been negative. After 6 
months, the lipoatrophic areas improved signifi cantly and no 
new skin lesions were observed.
We have presented a case of severe lipoatrophy in a 
patient with diabetes. A type III hypersensitivity reaction 
could explain the symptoms because of the detection of 
precipitins to insulins used by the patient. On the other hand, 
the lack of an abnormal deposit of immunological components 
does not support this hypothesis but, as the biopsied area 
corresponded to an old lesion, the immunological deposits 
might have been eliminated over time. The excipients of all 
the insulins were tested and no correlation was observed 
with the results obtained. Although the frequency of this 
cutaneous complication of insulin therapy has decreased since 
the introduction of various short- and long-acting insulin 
analogues, lipoatrophy can also develop after treatment with 
these compounds. 
The precipitin technique has been used in insulin resistance 
and immunity studies since the 1940s [7]. In the case described, 
the technique proved, once again, to be a valid method for 
choosing the most appropriate insulin. However, whether or not 
an immunological mechanism was involved in the lipoatrophic 
process remains uncertain, and further studies with adequate 
immunological assessment are necessary.
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Figure. Brownish plaque that appeared on the right knee 45 minutes 
after ingestion of a cumulative dose of 7.5 mg of meloxicam.
Fixed drug eruption (FDE) is a common cutaneous adverse 
drug reaction involving a delayed T-cell hypersensitivity 
reaction [1]. The most characteristic finding of FDE is 
recurrence of similar lesions at the same sites and healing with 
residual hyperpigmentation [2]. FDE appears within minutes 
to several hours after intake [1]. Rechallenge is the most 
reliable method of identifying causative drugs, but application 
of patch tests, especially in the affected area, has gained the 
most attention to date [1]. Nonsteroidal anti-infl ammatory 
drugs (NSAID) are one of the principal causes of FDE [3]. 
Although a few cases of piroxicam-induced FDE have been 
reported [4-7], FDE caused by oxicams is rare. We report an 
unusual case of FDE due to meloxicam. To the best of our 
knowledge, this is the fi rst report of FDE due to meloxicam.
A 44-year-old woman with rheumatic disease was 
referred to our clinic for assessment of several episodes of 
cutaneous eruption after ingestion of analgesics. She had 
a history of brownish, sharply demarcated, round pruritic 
plaques suggestive of FDE on the right knee and forearm with 
concomitant vulvar pruritus 10-15 minutes after oral intake 
of fl urbiprofen, ibuprofen, and piroxicam. The last reaction 
occurred 4 years ago. At presentation, the patient had no 
residual lesion. Because of her underlying rheumatic disease, 
she needed a safe NSAID. Considering the safety profi le of 
meloxicam in patients with aspirin-exacerbated respiratory 
diseases (AERD) and aspirin-induced urticaria [8,9], we 
performed a single-blind placebo-controlled oral challenge test 
with increasing doses of meloxicam up to a cumulative dose 
of 7.5 mg. No reaction occurred with the placebo. However, 
45 minutes after ingestion of meloxicam, the patient reported 
vulvar pruritus, and a brownish pruritic plaque appeared on the 
right knee (Figure). The reaction responded well to a topical 
corticosteroid. Four weeks later, cross-reactivity within the 
group was analyzed using patch tests with 0.1% piroxicam, 
1% piroxicam, 1% tenoxicam, 1% meloxicam, and 10% 
nimesulide, all in white petrolatum, on both the previously 
affected area (right knee) and unaffected skin (back). Only 
1% piroxicam on previously affected skin was positive at 72 
hours, and the results of the remaining patch tests with oxicams 
and nimesulide were negative. Subsequently, oral challenge 
tests with nimesulide and naproxen were performed, and both 
were negative.
